Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHOD0031 pediatric intermediate-risk Hodgkin disease response-adapted therapy trial
NL-OMON25408Recruiting
- Sponsor
- Children's Oncology Group
- Start
- May 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of doxorubicin, bleomycin, vincristine, etoposide, prednisone and 4 more in Hodgkin lymphoma (HL) (4 arms), sponsored by Children's Oncology Group. Primary endpoints: Event-free survival and Key toxicity occurrence. Started May 2006; status: recruiting.
02
Drugs
doxorubicinbleomycinvincristineetoposideprednisone
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NL-OMON25408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25408.